Cowen and Company’s Redhill Biopharma RDHL Stock Holding History

Cowen and Company’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,520	Closed	-$346K	–	672
2023 Q2	$346K	Buy	+11,520	New	+$664K	0.03%	193

Other funds holding RDHL

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

MOS

MGO One Seven Beachwood, Ohio $6.06B AUM 28.9% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Cowen and Company's RDHL Position: Q3 2023 in Review

Cowen and Company sold out of Redhill Biopharma (RDHL) in Q3 2023, closing a stake of 11,520 shares — an estimated $346K sold.

Cowen and Company first reported a position in RDHL in Q2 2023 and held it in 1 quarter. The position peaked at $346K in Q2 2023. 17 funds tracked by Wall St. Rank hold RDHL as of Q3 2023.

Cowen and Company reported no remaining Redhill Biopharma position as of Q3 2023 after selling out during the quarter.
Cowen and Company sold 11,520 Redhill Biopharma shares in Q3 2023, an estimated $346K.
Cowen and Company first reported a position in Redhill Biopharma in Q2 2023 and held it in 1 quarter.
Cowen and Company's Redhill Biopharma position peaked at $346K in Q2 2023.
17 funds tracked by Wall St. Rank held Redhill Biopharma as of Q3 2023.

Based on Cowen and Company's 13F filing for Q3 2023, filed 9 Nov 2023.